SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2025

Segment revenues and profits for the three and nine months ended September 30, 2025 and 2024 were as follows:


	Vision Care				Pharmaceuticals				Surgical				Total
	Three Months Ended September 30,
(in millions)	2025		2024		2025		2024		2025		2024		2025		2024
Revenues
Product Sales	$	734	$	682	$	329	$	305	$	214	$	205	$	1,277	$	1,192
Other Revenues	2		2		1		1		1		1		4		4
	736		684		330		306		215		206		1,281		1,196

Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	279		252		106		93		124		119
Cost of other revenues	—		—		1		—		—		—
Selling, general and administrative	225		219		132		137		72		64
Research and development	15		12		15		7		11		10
Segment Profit	$	217	$	201	$	76	$	69	$	8	$	13	301		283
Corporate													(153)		(146)
Amortization of intangible assets													(68)		(72)
Other income (expense), net													15		(22)
Operating income													95		43
Interest income													3		4
Interest expense													(101)		(100)
Loss on extinguishment of debt													3		—
Foreign exchange and other													(3)		(5)
Loss before provision for income taxes													$	(3)	$	(58)


	Vision Care				Pharmaceuticals				Surgical				Total
	Nine Months Ended September 30,
(in millions)	2025		2024		2025		2024		2025		2024		2025		2024
Revenues
Product Sales	$	2,139	$	2,010	$	902	$	881	$	641	$	608	$	3,682	$	3,499
Other Revenues	6		6		4		2		4		4		14		12
	2,145		2,016		906		883		645		612		3,696		3,511

Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	820		735		303		274		390		360
Cost of other revenues	—		—		4		2		—		—
Selling, general and administrative	689		674		439		385		218		195
Research and development	34		36		36		22		34		29
Segment Profit	$	602	$	571	$	124	$	200	$	3	$	28	729		799
Corporate													(497)		(459)
Amortization of intangible assets													(202)		(220)
Other expense, net													(29)		(45)
Operating income													1		75
Interest income													9		10
Interest expense													(323)		(301)
Loss on extinguishment of debt													(6)		—
Foreign exchange and other													(11)		(8)
Loss before provision for income taxes													$	(330)	$	(224)

Revenues by segment and product category were as follows:


	Vision Care				Pharmaceuticals				Surgical				Total
	Three Months Ended September 30,
(in millions)	2025		2024		2025		2024		2025		2024		2025		2024
Pharmaceuticals	$	1	$	1	$	279	$	246	$	—	$	—	$	280	$	247
Devices	270		250		—		—		214		205		484		455
OTC	454		420		—		—		—		—		454		420
Branded and Other Generics	9		11		50		59		—		—		59		70
Other revenues	2		2		1		1		1		1		4		4
	$	736	$	684	$	330	$	306	$	215	$	206	$	1,281	$	1,196

	Nine Months Ended September 30,
	2025		2024		2025		2024		2025		2024		2025		2024
Pharmaceuticals	$	3	$	3	$	759	$	698	$	—	$	—	$	762	$	701
Devices	763		716		—		—		641		608		1,404		1,324
OTC	1,344		1,262		—		—		—		—		1,344		1,262
Branded and Other Generics	29		29		143		183		—		—		172		212
Other revenues	6		6		4		2		4		4		14		12
	$	2,145	$	2,016	$	906	$	883	$	645	$	612	$	3,696	$	3,511

Bausch & Lomb Corp 10-Q